Leading pharmaceutical conglomerate Johnson & Johnson announced that it has reached an agreement to acquire Alios BioPharma for about $1.75 billion.
According to reports, J&J’s takeover of the biopharmaceutical company will expand its portfolio of medications used to treat viral infections. Alios currently owns a compound in Phase II trials to treat infants with respiratory syncytial virus, the last major pediatric disease with no preventative therapy, according to reports.
The takeover remains subject to regulatory approval, though the companies expect to complete the takeover in the fourth quarter of this year.
Full content: Pharmaceutical Business Review
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI